IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety
News provided by
Share this article
Share this article
FRESNO, Calif., May 27, 2021 /PRNewswire/ Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering from depression or anxiety. The GeneSight® test, offered through Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, helps clinicians and patients better understand how a particular individual may respond to certain medications.
GeneSight is a psychotropic test that analyzes how a person s genes impact how they may break down or respond to medications commonly prescribed to treat depression, anxiety, and other psychiatric conditions. Now, with a simple cheek swab, clinicians can learn which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on a person s